Clinical Trial Update: Tislelizumab in Addition to BACE in Patients with NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding tislelizumab to the BACE regimen in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: NSCLC | Phase 2 | Status: COMPLETED